ArticleJournal of translational medicine2025
Real-world evidence for repurposing hydralazine as a potential epigenetic modulator for psoriasis: a 16-year retrospective nationwide cohort study.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hydralazine potentiates the antiproliferative effect of photodynamic therapy on Candida albicans and Candida parapsilosis in vitro.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDysregulated DNA methylation and hypertension (HTN) are closely associated with the development of psoriasis. However, the impact of the vasodilator hydralazine (HLZ), which also inhibits DNA methyltransferase, on psoriasis risk remains unclear. This study investigated the association of HLZ use with the risk of psoriasis and the severity of incident psoriasis.
methodsThis nationwide cohort study utilized data from the Taiwan Longitudinal Generation Tracking Database (2000–2015). We compared three propensity score-matched groups: patients with HTN treated with HLZ (HTN and HLZ cohort, n = 61,794), patients with HTN on other antihypertensives (HTN and non-HLZ cohort, n = 247,176), and patients without HTN (non-HTN cohort, n = 247,176).
resultsPatients with HTN using HLZ exhibited a lower risk of psoriasis than those using other antihypertensive agents [adjusted hazard ratio (aHR): 0.786, 95% CI: 0.535–0.930, p = 0.015]. Furthermore, the HTN and HLZ cohort was associated with a lower likelihood of requiring systemic treatment (aHR: 0.672, 95% CI: 0.522–0.894, p < 0.001) and linked to a lower risk of cause-specific mortality (aHR: 1.531 vs. 1.625, p < 0.001).
conclusionsIn this large-scale observational study, HLZ use was associated with a lower risk and reduced severity of incident psoriasis in patients with HTN. While these findings cannot establish causality, they provide compelling real-world evidence to support further investigation into repurposing HLZ as a potential epigenetic modulator for psoriasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.